CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS

CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y122 AND CYP2Y123 POLYMORPHISMS

Aim. This study aimed to look at the characteristics of the P2Y12 reactivity unit (PRU) in 30 Minang acute coronary syndrome (ACS) patients in Dr. M. Djamil Hospital, Padang, Indonesia.Material and methods. This research was a cross-sectional study conducted in September 2016. The effectiveness of c...

Full description

Saved in:

Bibliographic Details
Main Authors:	R. Rahmatini, G. Aliska, M. Syafri, A. Achyar
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2018-04-01
Series:	Российский кардиологический журнал
Subjects:	acute coronary syndrome clopidogrel cyp2c19 polymorphism pru
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/2659
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PEAR1, PON1, CYP2C19, CYP1A2 and F2R Polymorphisms are Associated with MACE in Clopidogrel-Treated Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
by: Du P, et al.
Published: (2024-12-01)

The Frequency of CYP2C19&ast;2 Gene Polymorphisms in Burkina Faso Patients Treated with Clopidogrel
by: Kagambèga YD, et al.
Published: (2025-05-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Preliminary Data from a Study on Polymorphism RS4244285 of P4502c19 Cytochrome Gene in Patients with Acute Coronary Syndrome, Undergoing Treatment with Dual Antiplatelet Therapy With Clopidogrel and Aspirin
by: Katya Kovacheva, et al.
Published: (2016-09-01)

CYP2C19 polymorphism and coronary in-stent restenosis: A systematic review and meta-analysis [version 3; peer review: 2 approved, 1 approved with reservations]
by: Ivana Purnama Dewi, et al.
Published: (2025-01-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

CYP2C19 Phenotype, P2Y12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy
by: Rajiv C. Patel, et al.
Published: (2025-07-01)

The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease
by: Nour Haj Saleh, et al.
Published: (2025-04-01)

THE ROLE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER THE EMERGENCE OF MORE POWERFUL INHIBITORS OF P2Y12 RECEPTOR
by: S. R. Gilyarevsky, et al.
Published: (2014-07-01)

NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: K. B. Mirzaev, et al.
Published: (2018-03-01)

The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients
by: Salha Jokhab, et al.
Published: (2025-04-01)

Polymorphisms of CYP1A1, CYP1A2, CYP19, and SULT1A1 genes in women with early miscarriage
by: I. N. Noskova, et al.
Published: (2019-12-01)

Clopidogrel therapy in acute coronary syndrome: Contemporary issues
by: Satyavir Yadav, et al.
Published: (2025-07-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Computational drug–drug interaction prediction mediated by CYP450 isoforms of Ilaprazole coadministered with clopidogrel
by: Priyadharshini Ananthathandavan, et al.
Published: (2024-12-01)

Effectiveness of clopidogrel vs. ticagrelor based on the ABCD-GENE score in acute coronary syndrome patients following percutaneous coronary intervention
by: Xiaotong Xu, et al.
Published: (2025-06-01)

CYP2C19 variability and clinical outcomes of clopidogrel, proton pump inhibitors, and voriconazole in Southeast Asia: a systematic review and meta-analysis
by: Harri Hardi, et al.
Published: (2025-06-01)

POLYMORPHISMS OF THE CYP1A1, CYP1A2, CYP19, AND SULT1A1 GENES ARE NOT ASSOCIATED WITH INFERTILITY IN WOMEN WITH GENITAL ENDOMETRIOSIS
by: LARISA N. Danilova, et al.
Published: (2018-09-01)

Regional aspects of associations of the CYP2C19 gene polymorphism with coronary atherosclerosis in acute coronary syndrome
by: K. Yu. Nikolaev, et al.
Published: (2018-11-01)

THE PROTOCOL: INFLUENCE OF THE COMBINATION CARRIAGE СУР2С19*2 AND *17 ON EFFICACY OF CLOPIDOGREL
by: Е. М. Zelenskaya, et al.
Published: (2017-11-01)

CYP2D6 polymorphism rs1065852 significantly increases the risk of type 2 diabetes
by: Huiyi Wei, et al.
Published: (2025-12-01)

ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY?
by: S. J. Martsevich
Published: (2016-01-01)

PREVALENCE OF POLYMORPHOUS LOCUS 681G>A OF CYP2C19 GENE IN RUSSIAN POPULATION
by: T. A. Bairova, et al.
Published: (2014-11-01)

Prevalence of CYP2C19 Variants in Patients with Cardiovascular Disease from the Yunnan-Guizhou Plateau in Southwestern China
by: Li XP, et al.
Published: (2025-05-01)

CYP2C9 Polymorphism is not Associated with Elevated Carcinoembryonic Antigen Levels
by: Claire Hall, et al.
Published: (2019-04-01)

GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA
by: K. B. Mirzaev, et al.
Published: (2015-10-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure
by: Kayla R. Tunehag, et al.
Published: (2025-01-01)

Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA stratified by age and renal function: CHANCE-2 trial substudy
by: Yu Wu, et al.
Published: (2025-12-01)

GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES
by: A. N. Repin, et al.
Published: (2015-10-01)

CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms
by: Yuqing Zhang, et al.
Published: (2024-12-01)

Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
by: Inger Johansson, et al.
Published: (2025-05-01)

CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation
by: A. A. Kurylev, et al.
Published: (2018-05-01)

Association of CYP2D6*4 Polymorphism With Response to Atorvastatin in Patients With High Low-Density Lipoprotein Level in Northern Iran, Guilan Provice
by: Raziyeh Asadollahpour, et al.
Published: (2023-04-01)

DISTRIBUTION OF POLYMORPHIC VARIANTS OF THE CYP1A1 AND CYP1A2 GENES IN THE MONGOLOID AND CAUCASOID POPULATION OF THE SOUTH OF KUZBASS
by: Фаина Анисимовна Лузина, et al.
Published: (2021-08-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation
by: Vavić Neven, et al.
Published: (2016-01-01)

Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel
by: O. O. Shakhmatova
Published: (2022-06-01)

Effect of <i>CYP1A2</i>, <i>CYP2D6</i>, and <i>CYP3A4</i> Variation on Antipsychotic Treatment Outcomes
by: Lauren Varney, et al.
Published: (2025-06-01)

Clopidogrel effects on thrombolysis effectiveness and clinical course of ST elevation myocardial infarction (30-day follow-up)
by: S. V. Shalaev, et al.
Published: (2007-08-01)

Efficacy and safety of antipsychotics in adolescents with an acute psychotic episode in relation to the activity of CYP3A and CYP2D6 isoenzymes
by: D. V. Ivashchenko, et al.
Published: (2020-12-01)